Baidu
map

Blood:艾曲波帕(eltrombopag)可在IFNγ介导的炎性环境中维持人造血干/祖细胞的存活和功能

2019-04-01 不详 MedSci原创

中心点:在人类HSPCs中,IFNγ过剩会扰乱TPO诱导的信号通路;艾曲波帕(eltrombopag)可通过克服这种抑制从而增强HSPC功能。通过TPO:IFNγ异构体封闭TPO上的与c-MPL结合的低亲和力结合位点,有助于干扰TPO信号。摘要:在免疫介导的骨髓衰竭综合征(BMF)中,促炎细胞因子干扰素-γ(IFNγ)参与人类造血干细胞和祖细胞(HSPC)的耗竭。Luigi J. Alvarado

中心点:

在人类HSPCs中,IFNγ过剩会扰乱TPO诱导的信号通路;艾曲波帕(eltrombopag)可通过克服这种抑制从而增强HSPC功能。

通过TPO:IFNγ异构体封闭TPO上的与c-MPL结合的低亲和力结合位点,有助于干扰TPO信号。

摘要:

免疫介导的骨髓衰竭综合征(BMF)中,促炎细胞因子干扰素-γ(IFNγ)参与人类造血干细胞和祖细胞(HSPC)的耗竭。

Luigi J. Alvarado等人发现IFNγ可通过封闭低亲和力结合位点特异性的阻断促血小板生成素(TPO,HSPC存活的主要调控因子)与其受体(c-MPL)的识别结合,进而扰乱TPO诱导的信号通路,影响人HSPCs的存活。

艾曲波帕,一种合成的小分子TPO类似物,与c-MPL在不同于TPO胞外结合位点的位置相互作用,绕过了上述的抑制,从而解释了为何艾曲波帕在内源性TPO水平已经升高的情况下,仍在BMF中具有临床活性。

因此,IFNγ介导的TPO:IFNγ复合物形成紊乱以及所导致的生长因子细胞信号的重要通路抑制或可代表IFNγ损害人HPSCs功能的一般机制。这一发现或可为各类慢性炎性疾病提供广泛的治疗应用。


原始出处:

Luigi J. Alvarado, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFNγ.Blood 2019 :blood-2018-11-884486; doi: https://doi.org/10.1182/blood-2018-11-884486 

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-06-19 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-04-03 俅侠
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1690749, encodeId=35951690e4903, content=<a href='/topic/show?id=27289466c8' target=_blank style='color:#2F92EE;'>#IFNγ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9466, encryptionId=27289466c8, topicName=IFNγ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5f629121759, createdName=fangcong, createdTime=Wed Jun 19 09:26:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708131, encodeId=b6e51e081319d, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Wed Oct 30 23:26:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420130, encodeId=4d57142013088, content=<a href='/topic/show?id=7a7286e7153' target=_blank style='color:#2F92EE;'>#艾曲波帕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86771, encryptionId=7a7286e7153, topicName=艾曲波帕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776e3562469, createdName=huangdf, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512464, encodeId=e0d91512464d1, content=<a href='/topic/show?id=f802e4102cb' target=_blank style='color:#2F92EE;'>#祖细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74102, encryptionId=f802e4102cb, topicName=祖细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f18310470858, createdName=12498636m52(暂无昵称), createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519043, encodeId=d194151904311, content=<a href='/topic/show?id=ba989452f5' target=_blank style='color:#2F92EE;'>#IFN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9452, encryptionId=ba989452f5, topicName=IFN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b711235060, createdName=bugit, createdTime=Wed Apr 03 03:26:00 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-04-03 bugit

相关资讯

NEJM:艾曲波帕可改善难治性再生障碍性贫血

       《新英格兰医学杂志》(N Engl J Med)7月5日发表的一项研究表明在一些难治性重度再生障碍性贫血患者中,用艾曲波帕治疗与多系临床缓解相关。        免疫抑制疗法或同种异体移植可有效地治疗重度再生障碍性贫血(以免疫介导的骨髓发育不全和全血细胞减少为特征)。1/3

NEJM:添加艾曲波帕的免疫抑制治疗有望成为重症再生障碍性贫血一线治疗方案

对于重症再生障碍性贫血患者,加入艾曲波帕的免疫抑制治疗可显着提高患者血液学反应率

Blood:Eltrombopag(艾曲波帕)用于ITP成年患者的长期安全性和有效性

在2/3期试验中,用Eltrombopag(艾曲波帕)治疗慢性/持续性免疫性特发性血小板减少症(ITP)≤6个月即可增加血小板计数、减少出血。

Blood:阿扎胞苷疗法联合艾曲波帕治疗MDS患者,会恶化其血小板减少

中心点:对于高危型MDS患者,根据血小板相关结点和存活结点,艾曲波帕/阿扎胞苷的疗效不优于安慰剂/阿扎胞苷摘要:采用阿扎胞苷治疗MDS,通常会在第一疗程加重血小板减少症。SUPPORT是一个随机化的双盲、安慰剂为对照的III期研究,研究在阿扎胞苷治疗的同时予以艾曲波帕,对血小板的支持作用。招募了基础血小板低于75x109/L的IPSS 中级-1、中级-2或高危型MDS患者,按1:1随机分至艾曲波帕

Lacnet:艾曲波帕对慢性免疫性血小板减少症儿童患者是有效的

对患有慢性免疫性血小板减少症的成年患者,促血小板生成素受体激动剂艾曲波帕被证明是安全、可耐受、且有效的。研究者进行了一项研究(PETIT2),探究该药物对慢性免疫性血小板减少症的儿童患者的安全性和有效性。PETIT2是在12个国家38个中心进行的随机、多中心、安慰剂对照试验。参与者为1-17岁慢性免疫性血小板减少症患者,其血小板计数低于30 × 109 /L,将其随机分为艾曲波帕组和对照组。研究者

FDA扩大了艾曲波帕片在ITP中的使用年龄

美国食品和药物管理局(FDA)近期宣布,它已经扩大了艾曲波帕片(eltrombopag (Promacta, Novartis))在一种罕件的血液紊乱病--慢性免疫性血小板减少性紫癜(ITP)中的使用年龄,包括1岁的的患儿也能使用该药。这则消息紧接着FDA在6月份的决定,要扩大该药在6岁及以上患儿的使用指标。通常,ITP患者血小板水平会异常的低。FDA在发布这则消息时说道:“人

Baidu
map
Baidu
map
Baidu
map